Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
PHP Toggle Menu

Category: 2024

Transgene’s Combined General Meeting of May 15, 2024

General meeting 2024

Published 15 May 2024
Categorized as 2024, Press release

Transgene provides business and financial update for Q1 2024

Financial update Q1 2024

Published 14 May 2024
Categorized as 2024, Press release

Availability of of Preparatory Documents for the Combined General Meeting of May 15, 2024

Shareholders’ meeting 2024

Published 24 April 2024
Categorized as 2024, Press release

Availability of Transgene’s 2023 Universal Registration Document

URD 2023

Published 11 April 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release

Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024

TG4050 AACR 2024

Published 9 April 2024
Categorized as 2024, Myvac, Press release, TG4050

Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers

A. Lalanne, et al. AACR 2024  Abstract available on the AACR website – Download the poster Poster Presentation

Published 9 April 2024
Categorized as 2024, Myvac, Publication, TG4050

Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer

appointment Lucie Larguier et Christelle Schwoerer

Published 27 March 2024
Categorized as 2024, Press release

Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025

2023 financial results and business update

Published 27 March 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release

Transgene Announces Upcoming Investor Meetings

upcoming investor meetings

Published 18 March 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release

Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024

TG4050 AACR 2024

Published 6 March 2024
Categorized as 2024, categorie-orpheline, dates, dates, Myvac, Press release, TG4050

Posts pagination

Newer posts Page 1 … Page 3 Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
Menu